- Home
- ZCMD vs NXTS Comparison
ZCMD vs NXTS Comparison
Compare ZCMD & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZCMD | NXTS |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Agricultural Chemicals |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.4M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZCMD | NXTS |
|---|---|---|
| Price | $1.00 | $1.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 17.1K |
| Earning Date | 04-28-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.55 |
| 52 Week High | $11.96 | $23.80 |
Technical Indicators
Market Signals| Indicator | ZCMD | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 37.11 |
| Support Level | $0.72 | $1.43 |
| Resistance Level | $0.97 | $2.03 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 59.72 | 36.96 |
Price Performance
Historical ComparisonAbout ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.